Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study

[1]  A. Buist.  Guidelines for the management of chronic obstructive pulmonary disease. , 2002, Respiratory medicine.

[2]  C. Mapp.  Inhaled glucocorticoids in chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.

[3]  W. Bailey,et al.  Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. , 2000, American journal of respiratory and critical care medicine.

[4]  M. Cazzola,et al.  Long acting β2 agonists and theophylline in stable chronic obstructive pulmonary disease , 1999, Thorax.

[5]  H. Boushey.  Glucocorticoid therapy for chronic obstructive pulmonary disease. , 1999, The New England journal of medicine.

[6]  S. Christensen,et al.  Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. , 1999, Pulmonary pharmacology & therapeutics.

[7]  S. Christensen,et al.  Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pig. , 1998, The Journal of pharmacology and experimental therapeutics.

[8]  S. Christensen,et al.  SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo. , 1998, The Journal of pharmacology and experimental therapeutics.

[9]  P. Barnes,et al.  Chronic obstructive pulmonary disease: new opportunities for drug development. , 1998, Trends in pharmacological sciences.

[10]  P. Jeffery,et al.  Structural and inflammatory changes in COPD: a comparison with asthma. , 1998, Thorax.

[11]  T. Torphy.  Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. , 1998, American journal of respiratory and critical care medicine.

[12]  J. G. Douglas,et al.  Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. , 1997, Thorax.

[13]  L. Fernandes,et al.  PHOSPHODIESTERASE INHIBITORS AND ENDOTHELIN AS MODULATORS OF RESPIRATORY NEUROTRANSMISSION , 1996, Clinical and experimental pharmacology & physiology.

[14]  John L. Hankinson,et al.  Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[15]  J C Yernault,et al.  Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. , 1995, The European respiratory journal.

[16]  B. Make,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[17]  P. Jones,et al.  A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. , 1992, The American review of respiratory disease.

[18]  I Biaggioni,et al.  Caffeine and theophylline as adenosine receptor antagonists in humans. , 1991, The Journal of pharmacology and experimental therapeutics.

[19]  Y. Hochberg.  A sharper Bonferroni procedure for multiple tests of significance , 1988 .

[20]  R M Gardner,et al.  Reference spirometric values using techniques and equipment that meet ATS recommendations. , 2015, The American review of respiratory disease.